Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab.

Trial Profile

Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Basiliximab
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Sep 2009 Planned end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 17 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top